OMX Copenhagen PI
1.155,22
PKT
+18,63
PKT
+1,64
%
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 15.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 11.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 10.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 09.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 08.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 04.02.21 | Novo Nordisk overweight | Barclays Capital | |
| 04.02.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Neutral | UBS AG | |
| 03.02.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 26.01.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.01.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 20.01.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 20.01.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 18.01.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 18.01.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 15.01.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 15.01.21 | A.P. Moeller - Maersk A-S (B) overweight | Morgan Stanley | |
| 14.01.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 14.01.21 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 12.01.21 | A.P. Moeller - Maersk A-S (B) buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 12.01.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 04.01.21 | Novo Nordisk kaufen | JP Morgan Chase & Co. | |
| 17.12.20 | Novo Nordisk Neutral | UBS AG | |
| 04.12.20 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 01.12.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 23.11.20 | A.P. Moeller - Maersk A-S (B) kaufen | Credit Suisse Group | |
| 23.11.20 | A.P. Moeller - Maersk A-S (B) kaufen | Goldman Sachs Group Inc. |